Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution

被引：13

作者：

Wolfe, Cindy ^{[1
]}

Pagano, Paul ^{[1
]}

Pillar, Chris M. ^{[1
]}

Shinabarger, Dean L. ^{[1
]}

Boulos, Ramiz A. ^{[2
,3
]}

机构：

[1] Micromyx LLC, Kalamazoo, MI USA

[2] Flinders Univ S Australia, Sch Chem & Phys Sci, Bedford Pk, SA, Australia

[3] Boulos & Cooper Pharmaceut Pty Ltd, Antibiot Dev, Balcatta, WA, Australia

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2018年 / 92卷 / 03期

关键词：

Antibiotic resistance; Fidaxomicin; C; difficile; CDI; Ramizol; SUSCEPTIBILITY; RECURRENCE;

D O I：

10.1016/j.diagmicrobio.2018.06.002

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Antibiotic drug development remains a major challenge with few candidates in clinical development Ramizol, a first-in-class styrylbenzene antibiotic, is under development for the treatment of Clostridium difficile associated disease. Here, we investigate the in vitro antibacterial activity of Ramizol in comparison to fidaxomicin, vancomycin and metronidazole against 100 clinical isolates of C. difficile by the broth microdilution method. We show there is no apparent impact of ribotype, toxin-production, or resistance to fidaxomicin, vancomycin or metronidazole on the activity of Ramizol. Moreover, we show Ramizol has a narrower MIC range translating to potentially better control over the therapeutic dose. Together, these results support the further development of Ramizol for the treatment of C. difficile associated disease. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：250 / 252

页数：3

共 18 条

[1]

[Anonymous], 2017, Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement

[2]

[Anonymous], ANTIBACTERIAL AGENTS

[3]

[Anonymous], CLIN DEV SUCC RAT 20

[4]

[Anonymous], 2015 MED DEV CANC

[5]

[Anonymous], 2013, ANT RES THREATS US, P1, DOI DOI 10.1016/J.MEDMAL.2007.05.006,2013

[6] Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection [J].

Baines, Simon D. ;

Wilcox, Mark H. .

ANTIBIOTICS-BASEL, 2015, 4 (03) :267-298

[7]

CLSI, 2012, M11A8 CLSI

[8] Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials [J].

Crook, Derrick W. ;

Walker, A. Sarah ;

Kean, Yin ;

Weiss, Karl ;

Cornely, Oliver A. ;

Miller, Mark A. ;

Esposito, Roberto ;

Louie, Thomas J. ;

Stoesser, Nicole E. ;

Young, Bernadette C. ;

Angus, Brian J. ;

Gorbach, Sherwood L. ;

Peto, Timothy E. A. .

CLINICAL INFECTIOUS DISEASES, 2012, 55 :S93-S103

[9] Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications [J].

Debast, Sylvia B. ;

Bauer, Martijn P. ;

Sanders, Ingrid M. J. G. ;

Wilcox, Mark H. ;

Kuijper, Ed J. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (06) :1305-1311

[10] Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection [J].

Goldstein, Ellie J. C. ;

Citron, Diane M. ;

Sears, Pamela ;

Babakhani, Farah ;

Sambol, Susan P. ;

Gerding, Dale N. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (11) :5194-5199

← 1 2 →